Multicenter clinical trial, randomized, stratified, open and compared in patients with advanced NSCLC treated with Racotumomab or Nimotuzumab, vs Docetaxel after first line treatment oncospecific.

Trial Profile

Multicenter clinical trial, randomized, stratified, open and compared in patients with advanced NSCLC treated with Racotumomab or Nimotuzumab, vs Docetaxel after first line treatment oncospecific.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Racotumomab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms RANIDO
  • Most Recent Events

    • 11 Oct 2016 Results investigating racotumomab or nimotuzumab as a switch maintenance therapy in non progressor patients (n=237), presented at the 41st European Society for Medical Oncology Congress
    • 29 Sep 2015 Results presented at the European Cancer Congress 2015
    • 23 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top